Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C-Reference-Cited by-同舟云学术

Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C

Published:2022-10-11 Issue:11 Volume:5 Page:1169-1180
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Stephenson Clarke Joseph R.,Douglas Leon R.¹,Duriez Patrick J.²,Balourdas Dimitrios-Ilias³⁴,Joerger Andreas C.³⁴^ORCID,Khadiullina Raniya⁵,Bulatov Emil⁵,Baud Matthias G. J.

Affiliation:

1. Cancer Research UK, Somers Building, University Hospital Southampton, Tremona Road, Southampton SO16 6YD, United Kingdom

2. Centre for Cancer Immunology, University Hospital Southampton, Coxford Road, Southampton SO16 6YD, United Kingdom

3. Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe University, Max-von-Laue-Straße 9, 60438 Frankfurt am Main, Germany

4. Buchmann Institute for Molecular Life Sciences and Structural Genomics Consortium, Max-von-Laue-Straße 15, 60438 Frankfurt am Main, Germany

5. Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia

Funder

Engineering and Physical Sciences Research Council

Royal Society

Russian Science Foundation

Deutsche Forschungsgemeinschaft

Kazan Federal University

Cancer Research UK

Publisher

American Chemical Society (ACS)

Subject

Pharmacology (medical),Pharmacology

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.2c00164

Reference65 articles.

1. p53, guardian of the genome

2. Surfing the p53 network

3. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

4. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules;2024-07-27

2. Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53;Drug Design, Development and Therapy;2024-07

3. Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators;Cell Death & Disease;2024-06-11

4. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy;Cancer Communications;2024-02-04

5. The Role of Non-Coding RNAs in Myelodysplastic Neoplasms;Cancers;2023-09-30